Abstract: The invention relates to a composition containing pheromones comprising a carrier solvent, and to the use thereof for preventing and/or treating the behavioural or medical problems linked to the stress of non-human mammals. The invention also relates to a device for diffusing such a composition into the ambient air, and to a kit comprising said composition.
Abstract: The invention relates to a succinate dehydrogenase inhibitor or a prodrug and/or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of reperfusion injury, such as ischemia-reperfusion injury, by inhibiting the accumulation of succinate, wherein the inhibitor or prodrug and/or pharmaceutically acceptable salt thereof is a cell-permeable reversible inhibitor of succinate dehydrogenase.
Type:
Application
Filed:
July 3, 2015
Publication date:
May 18, 2017
Inventors:
Edward CHOUCHANI, Thomas KRIEG, Michael Patrick MURPHY, Lorraine WORK, Christian FREZZA
Abstract: Embodiments of the invention involve treating skin afflictions by the topical or oral use of acetylcholinesterase inhibitor. By effectively reducing or eliminating the population of Demodex mites in affected skin areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method. Embodiments of the invention are useful for treating skin afflictions including common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis, acne necrotica milliaris, psoriasis, steroid induced dermatitis, primary irritation dermatitis and rosacea.
Abstract: The present invention relates to the administration of a novel compound advantageously efficacious as PDE? inhibitor and its effects on subjects with cancer. More specifically, the present invention is directed to a method for administering a compound having favorable geometric properties for interacting with the PDE? prenyl-binding pocket, namely has certain structural components such as a three-cyclic backbone and at least one benzoyl-moiety in a side chain having at least two substituents containing highly electronegative atoms and being linked to the backbone via an aliphatic chain, for treating a subject suffering from a disease such as cancer, in particular non-small-cell lung cancer. The presence of said structural components particularly contributes to an advantageous interaction with PDE?, in particular with amino acids deep in the binding pocket.
Type:
Application
Filed:
November 13, 2015
Publication date:
May 18, 2017
Inventors:
Xiao Jun Yao, Lai Han Leung, Lian Xiang Luo, Liang Liu
Abstract: The present invention relates to cancer markers that are predictive for cancer patent response to treatment with an m TOR inhibitor and a vascular disrupting agent. The present invention further relates to methods of treating a cancer patient subpopulation with a combination of an m TOR inhibitor and a vascular disrupting agent.
Abstract: Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. The present invention also relates to methods for treating diabetes, especially Type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis and related diseases, comprising administering an SGLT2 inhibitor and a dipeptidyl peptidase IV (DPP IV) inhibitor.
Abstract: The invention relates to compounds of formula (I) or the salts thereof, said compounds of formula (I) being selected from among the group consisting of homoeriodictyol (1), eriodictyol (2), hesperetin (3) and sterubin (4), for use in the treatment of an ailment which can be alleviated or prevented by influencing the serotonin level and the concentration of free fatty acids in the blood.
Type:
Application
Filed:
July 26, 2015
Publication date:
May 18, 2017
Applicant:
Symrise AG
Inventors:
Veronika Somoza, Barbara Rohn, Kathrin Liszt, Marc Pignitter, Christina Hochkogler, Jakob Ley, Sabine Widder, Gerhard Krammer
Abstract: The present invention provides a composition for regulating blood sugar. The composition comprises at least one yellow pigment extracted from a red mold product, wherein the said yellow pigment is Monascin, Ankaflavin, or combination of Monascin and Ankaflavin. Moreover, results of a variety of animal experiments have proved that this blood sugar regulating composition indeed possess the functionalities of: lowering Hyperglycemia induced by high energy diet, alleviating ROS and inflammatory caused by the Hyperglycemia, reduce AST and ALT value of liver as well as sarcosine value of kidney.
Abstract: Methods of treating neuropsychiatric disorders including affective disorders and addiction involve intranasal or transdermal administration of a substantially selective kappa-opioid-receptor agonist that is also a partial D2 agonist, such as the compound salvinorin A. Also disclosed are intranasal, transdermal and/or inhalation systems for delivering the kappa-opioid-receptor agonist.
Abstract: A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed. The method includes administering to the subject an effective amount of a coumarin derivative represented by formula (I), or a pharmaceutically acceptable salt or hydrate thereof: Each of R1 and R2 is independently (a) phenyl optionally substituted with alkoxy, alkyl, cyano, nitro, hydroxy, trifluoromethyl, amino, carboxy, alkoxycarbonyl, phenyl, or one or two halogen(s), (b) pyridyl, (c) alkyl, or (d) thienyl.
Abstract: Disclosed are novel stable compounds having anti-oxidant properties and methods of using the compounds for the treatment of diseases or injuries associated with oxidative stress.
Type:
Application
Filed:
January 31, 2017
Publication date:
May 18, 2017
Inventors:
Marc Bailie, Steven K. Duddy, Jim Herman
Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.
Abstract: Traction alopecia and other disorders related to mechanical pulling on hair are treated or prevented by administering a topical composition comprising an alpha-1 adrenergic receptor agonist, a muscarinic receptor agonist, a nicotinic receptor agonist, and/or a cholinesterase inhibitor, or electrical stimulation to contract the arrector pili muscle. Compositions and methods are disclosed herein for the treatment and prevention of hair loss disorders caused at least in part by repeated application of tensile force to hair, including, without limitation, traction alopecia.
Abstract: The present invention provides an allisartan isoproxil solid dispersion with high drug loading and stability. On that basis, it also provides an allisartan isoproxil pharmaceutical composition containing mentioned solid dispersion. Compared with available technologies, the mentioned allisartan isoproxil pharmaceutical composition is characterized by high stability, good dissolution performance, and improved patient compliance, etc.
Abstract: Provided herein are spray-dried particles comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound and methods of their preparation. Also provided herein are pharmaceutical compositions comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, method of their preparation, and their use for treating or preventing hepatitis C virus infection.
Type:
Application
Filed:
March 4, 2015
Publication date:
May 18, 2017
Applicant:
Idenix Pharmaceuticals LLC
Inventors:
Adel M. Moussa, Benjamin Alexander Mayes, Sindhura Ganga
Abstract: The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 (“mPGES-1”) inhibitor. Particularly, the present invention relates to a nanoparticulate formulation comprising an mPGES-1 inhibitor and one or more surface stabilizers; a process for preparing such formulation; and its use in treating pain and inflammation in a subject.
Abstract: The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.
Type:
Application
Filed:
November 22, 2016
Publication date:
May 18, 2017
Inventors:
Chunlin Tao, Chengzhi Yu, Forrest Arp, Paul Weingarten, Patrick Soon-Shiong
Abstract: The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus Cryptococcus or the genus Candida, and a use thereof. In addition, the present invention relates to a therapeutic agent for fungal infection caused by the genus Cryptococcus or the genus Candida, the therapeutic agent containing FK506 derivative. The pharmaceutical composition of the present invention, is harmless to the human body, and can make a great contribution to providing antifungal drugs with an excellent antifungal effect.
Type:
Application
Filed:
June 29, 2015
Publication date:
May 18, 2017
Inventors:
Yong Sun Bahn, Hyo Jeong Kwon, Yeo Joon Yoon, Yeon Hee Ban
Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
Type:
Application
Filed:
October 8, 2015
Publication date:
May 18, 2017
Applicant:
AbbVie Inc.
Inventors:
Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
Abstract: The invention provides various novel compositions of berberine in combination with pharmacologically active EPA and DHA, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity. Additionally, the pharmaceutical compositions of the invention are useful in treating and/or preventing atherosclerosis, heart diseases, neurodegenerative diseases, inflammation, cancers, as well as various liver diseases or disorders, such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver.
Abstract: A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.
Type:
Application
Filed:
January 30, 2017
Publication date:
May 18, 2017
Inventors:
Nicola Frances BATEMAN, Philip Alexander MACFAUL, Ian Alun NASH
Abstract: Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.
Abstract: Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. Aminopyridines channel blocking, combined with buffering and zwitterionic charge states make promising therapies for myelin diseases and as antibiotics.
Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
Type:
Application
Filed:
November 4, 2016
Publication date:
May 18, 2017
Inventors:
Thinnayam N. Krishnamurthy, Andrew Darke
Abstract: The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.
Abstract: The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
October 19, 2016
Publication date:
May 18, 2017
Inventors:
Brian P. KEARNEY, Anita A. MATHIAS, Srinivasan RAMANATHAN
Abstract: A composition containing apomorphine and a divalent metal cation, such as, for example, Zn2+, Ca2+, or Mg2+, is disclosed. The composition contains apomorphine and the divalent metal cation in a molar ratio of 2 or less. Optionally, the composition contains an antioxidant. The composition can be prepared as a medicament for treating Parkinson's disease.
Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.
Type:
Application
Filed:
January 19, 2017
Publication date:
May 18, 2017
Applicant:
Teva Pharmaceutical Industries, Ltd.
Inventors:
Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
Abstract: The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an inseparable combination of an opiate and at least one opiate antagonists with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for prevention of non-oral opiate abuse in opiate addicts.
Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
Type:
Application
Filed:
December 13, 2016
Publication date:
May 18, 2017
Inventors:
Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
Abstract: Disclosed are novel piperazine derivatives that act as agonists of the a7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.
Abstract: A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of a compound having the structure:
Type:
Application
Filed:
June 19, 2015
Publication date:
May 18, 2017
Applicants:
Lixte Biotechnology, Inc., The United States of America, as Represented by th e Secretary, Department of Health & Human Service
Inventors:
John S. Kovach, Zhengping Zhuang, Ki-eun Chang, Matthew Hall, Michael M. Gottesman
Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and proapoptotic agents for cancer therapy.
Abstract: [Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high dissolubility even in persons having low stomach acid, and that can also ensure dissolubility after being allowed to stand for a certain period of time. Another object is to provide a simple method for producing the oral solid preparation.
Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
Type:
Application
Filed:
January 31, 2017
Publication date:
May 18, 2017
Inventors:
NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
Type:
Application
Filed:
January 31, 2017
Publication date:
May 18, 2017
Inventors:
NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
Abstract: A method of treating hand-foot syndrome (palmar-plantar erythrodysesthesia) and symptoms associated therewith in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves topically administering a pharmaceutical composition comprising an effective amount of an alpha adrenergic receptor agonist, pharmaceutically acceptable salt thereof, or combinations thereof; and a pharmaceutically acceptable carrier to the affected areas of skin or to the hands and feet.
Abstract: Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-? inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-? inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.
Type:
Application
Filed:
June 17, 2015
Publication date:
May 18, 2017
Inventors:
Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Brian Lannutti, Todd Covey, Roger Ulrich, Dave Johnson, Tjeerd Barf, Allard Kaptein
Abstract: Pharmaceutical compositions for topical administration for the treatment of psoriasis are described, containing as active ingredient therapeutically effective quantities of 4,6-dimethyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine (I) and 2,4-O-(2-furanylmethylene)-1,3,5,6-tetra-O-methyl-D-glucitol combined with suitable excipients and/or diluents.
Type:
Application
Filed:
July 3, 2015
Publication date:
May 18, 2017
Inventors:
Daniele Biagioni, Carlo De Angelis, Lorenzo Scappaticci, Andrea Calcaterra
Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years
Abstract: Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.
Type:
Application
Filed:
June 15, 2016
Publication date:
May 18, 2017
Inventors:
Chengguo Dong, Yi Fan, Katerina Leftheris, Stephen D. Lotesta, Suresh B. Singh, Colin M. Tice, Wei Zhao, Yajun Zheng, Linghang Zhuang
Abstract: The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
Type:
Application
Filed:
January 16, 2017
Publication date:
May 18, 2017
Applicant:
Ironwood Pharmaceuticals, Inc.
Inventors:
Takashi NAKAI, Joel MOORE, Nicholas Robert PERL, Rajesh R. IYENGAR, Ara MERMERIAN, G-Yoon Jamie IM, Thomas Wai-Ho LEE, Colleen HUDSON, Glen Robert RENNIE, James JIA, Paul Allan RENHOWE, Timothy Claude BARDEN, Xiang Y. YU, James Edward SHEPPECK, Karthik IYER, Joon JUNG, George Todd MILNE, Kimberly Kafadar LONG, Mark G. CURRIE
Abstract: Oral dosage forms of osteoclast inhibitors, including some Bruton's tyrosine kinase (BTK) inhibitors, such as dasatinib can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
Abstract: Described are compositions and methods for treating an enveloped virus in a patient in need thereof. Exemplary enveloped viruses are those in the family Filoviridae and include Ebola virus.
Abstract: A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-?]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-?]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein.
Type:
Application
Filed:
September 23, 2016
Publication date:
May 18, 2017
Applicant:
Array BioPharma Inc.
Inventors:
David Shank Fry, Christopher M. Lindemann, Michael Preigh, Corey Jay Bloom, Christopher Donovan Craig, Devon Brevard Dubose, Jeff Gautschi, Dan Smithey
Abstract: The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as tyrosine kinase inhibitor, wherein R1, R2, R3, R3?, R4, R5, R6, X, L, T, Z and q are as defined in the specification. The invention also relates to a process for preparing the same, a pharmaceutical composition and a pharmaceutical formulation containing the derivative, use of the derivative for treating excessive proliferative diseases and chronic obstructive pulmonary disease and use of the derivative in the manufacture of a medicament for treating excessive proliferative diseases and chronic obstructive pulmonary disease.
Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
Type:
Application
Filed:
July 20, 2016
Publication date:
May 18, 2017
Inventors:
Steven P. Langston, Edward J. OLHAVA, Stepan VYSKOCIL
Abstract: The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance stability of entecavir, and a method for preparing the same. According to the present invention, the invention has an effect that entecavir can be stably maintained in a pharmaceutical preparation containing a certain amount or more of moisture by adding the antioxidizing agent, thereby a pharmaceutical preparation can be provided as a formulation containing a certain amount or more of moisture, for example, an orally disintegrating film formulation.
Type:
Application
Filed:
June 22, 2015
Publication date:
May 18, 2017
Inventors:
Hong Ryeol JEON, Do-Woo KWON, Bong-Sang LEE, Su-Jun PARK, Jiyeong HAN, Myeongcheol KIL, Min Seop KIM